Abstract:It is well-known that the potency of a drug is heavily associated with its kinetic and thermodynamic properties with the target. Nuclear receptors (NRs), as an important target family, play important roles in regulating a variety of physiological processes in vivo. However, it is hard to understand the drug-NR interaction process because of the closed structure of the ligand-binding domain (LBD) of the NR proteins, which apparently hinders the rational design of drugs with controllable kinetic properties. Therefore, understanding the underlying mechanism of the ligand-NR interaction process seems necessary to help NR drug design. However, it is usually difficult for experimental approaches to interpret the kinetic process of drug-target interactions. Therefore, in silico methods were utilized to explore the optimal binding/dissociation pathways of the NR ligands. Specifically, farnesoid X receptor (FXR) is considered here as the target system since it has been an important target for the treatment of bile acid metabolism-associated diseases, and a series of structures cocrystallized with diverse scaffold ligands were resolved. By using random acceleration molecular dynamics (RAMD) simulation and umbrella sampling (US), 5 main dissociation pathways (pathways I-V) were identified in 11 representative FXR ligands, with most of them (9/11) preferring to go through Pathway III and the remaining two favoring escaping from Pathway I and IV. Furthermore, key residues functioning in the three main dissociation pathways were revealed by the kinetic residue energy analysis (KREA) based on the US trajectories, which may serve as road-marker residues for rapid identification of the (un)binding pathways of FXR ligands. Moreover, the preferred pathways explored by RAMD simulations are in good agreement with the minimum free energy path identified by the US simulations with the Pearson R = 0.76 between the predicted binding affinity and the experimental data, suggesting that RAMD is suitable for applying in large-scale (un)binding-pathway exploration in the case of ligands with obscure binding tunnels to the target.

Ligand‐binding Regulation of LXR/RXR and LXR/PPAR Heterodimerizations: SPR Technology‐based Kinetic Analysis Correlated with Molecular Dynamics Simulation

Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ

Binding analyses between Human PPARgamma-LBD and ligands.

The molecular mechanism of hPPAR alpha activation

Binding analyses between Human PPARgamma-LBD and ligands. Surface plasmon resonance biosensor assay correlating with circular dichroic spectroscopy determination and molecular docking

Structural mechanism underlying ligand binding and activation of PPARγ

Molecular Recognition of Agonist and Antagonist for Peroxisome Proliferator-Activated Receptor-Α Studied by Molecular Dynamics Simulations.

Structurally Selective Mechanism of Liver X Receptor Ligand: in Silico and in Vitro Studies.

Coadministration Of A Liver X Receptor Agonist And A Peroxisome Proliferator Activator Receptor-Alpha Agonist In Mice: Effects Of Nuclear Receptor Interplay On High-Density Lipoprotein And Triglyceride Metabolism In Vivo

Ligand efficacy shifts a nuclear receptor conformational ensemble between transcriptionally active and repressive states

Bindings of PPAR<sub></sub> ligand-binding domain with 5-cholesten-3, 25-diol, 3-sulfate: accurate prediction by molecular simulation

Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA

Exploring Dual Agonists for PPARα/γ Receptors Using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.

Liver X receptors：the new orientation of drugs for metabolic diseases

Insights into the Interaction Mechanisms of Estrogen-Related Receptor Alpha (errα) with Ligands Via Molecular Dynamics Simulations

Exhaustively Exploring the Prevalent Interaction Pathways of Ligands Targeting the Ligand-Binding Pocket of Farnesoid X Receptor via Combined Enhanced Sampling

Three-Dimensional Pharmacophore Modeling of Liver-X Receptor Agonists

Communication between the Ligand-Binding Pocket and the Activation Function-2 Domain of Androgen Receptor Revealed by Molecular Dynamics Simulations

Ligand Binding and Heterodimerization with Retinoid X Receptor Α (rxrα) Induce Farnesoid X Receptor (FXR) Conformational Changes Affecting Coactivator Binding

Ligand-Dependent and -Independent Regulation of PPARγ and Orphan Nuclear Receptors

The Effect of Antagonists on the Conformational Exchange of the Retinoid X Receptor Alpha Ligand-Binding Domain